Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
McKinsey
Harvard Business School
Medtronic
AstraZeneca

Last Updated: December 6, 2022

CLINICAL TRIALS PROFILE FOR ENALAPRILAT


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Enalaprilat

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00226096 ↗ Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Completed National Health and Medical Research Council, Australia N/A 2005-11-01 The purpose of the study is to determine whether lowering high blood pressure levels after the start of a stroke caused by bleeding in the brain (intracerebral haemorrhage) will reduce the chances of a person dying or surviving with a long term disability. The study will be undertaken in two phases: a vanguard phase in 400 patients, to plan for a main phase in 2000 patients.
NCT00226096 ↗ Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Completed The George Institute N/A 2005-11-01 The purpose of the study is to determine whether lowering high blood pressure levels after the start of a stroke caused by bleeding in the brain (intracerebral haemorrhage) will reduce the chances of a person dying or surviving with a long term disability. The study will be undertaken in two phases: a vanguard phase in 400 patients, to plan for a main phase in 2000 patients.
NCT00741156 ↗ The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution Completed The Hospital for Sick Children Phase 3 2008-07-01 The primary objective of this study is to study the acute effects of angiotensin-converting enzyme inhibitor (ACEI) on systemic, pulmonary and cerebral blood flow in post bidirectional cavopulmonary connection (BCPC) patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Enalaprilat

Condition Name

Condition Name for Enalaprilat
Intervention Trials
Heart Failure 3
Hypertension 2
Bile Salt Export Pump (BSEP) Transporter 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Enalaprilat
Intervention Trials
Hypertension 4
Heart Failure 3
Cardiomyopathy, Dilated 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Enalaprilat

Trials by Country

Trials by Country for Enalaprilat
Location Trials
Australia 5
United States 4
Austria 2
Serbia 2
Netherlands 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Enalaprilat
Location Trials
Tennessee 2
District of Columbia 1
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Enalaprilat

Clinical Trial Phase

Clinical Trial Phase for Enalaprilat
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Enalaprilat
Clinical Trial Phase Trials
Completed 7
Unknown status 3
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Enalaprilat

Sponsor Name

Sponsor Name for Enalaprilat
Sponsor Trials
Ethicare GmbH 3
National Health and Medical Research Council, Australia 2
The George Institute 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Enalaprilat
Sponsor Trials
Other 16
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Merck
AstraZeneca
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.